Vishal Pendharkar
Group Leader- Therapeutic Innovation @Cancer Research Horizons
Signup · Get unlimited contacts
WORK HISTORY
Group Leader- Therapeutic Innovation @Cancer Research Horizons
Cambridgeshire, GB
Cancer Research Horizons is Cancer Research UK\'s innovation arm, translating discovery into breakthrough treatments. Therapeutic Innovation team runs multi‑site drug discovery programmes and partners globally to advance early‑stage oncology assets, including targeted small molecules and biologics. Uniting the strength of our network of world-class biology and cutting-edge technology platforms, We are a single organisation with multiple sites embedded in leading UK academic and biotech centres.
EDUCATION
Poona College of Pharmacy
M.Pharma, Pharmacology
Temasek Polytechnic
Certificate in Commercial Law and Technology Transfer, Law
National Institutes of Health
Principles of Clinical Pharmacology
Fatima High School, Ambernath
High School, English, Chemistry, Biology, Maths and physics
Government College of Pharmacy, Amravati
B.Pharma, Pharmacy
SKILLS
ABOUT VISHAL PENDHARKAR
Pharmacologist with more than 20 years of research and management experience. A passionate drug discovery scientist specialized in translating early discoveries to preclinical candidates that resulted in five IND filings, three out licensing deals and one spin-off. I approach every drug discovery project with a fresh perspective, taking a holistic and integrated approach to move the project forward. Mentored pharmacology and DMPK teams as a function head.Contributed in the preclinical development, successful IND filings and out-licensing of several assets- o Small molecule combination for HCV (CRx808)(discontinued after Phase 2a), o Small molecule porcupine inhibitor currently in Phase 1b (ETC-159) o Small molecule inhibitor of Mnk kinase out-licensed to AUM biosciences currently in Phase 1b (ETC-206) o An antibody drug conjugate for oncology currently in Phase 1b (EBC-129). o Successfully presented to the out licensing partners during the due diligence process. An anti- viral peptide project was out-licensed at can seek stage (EDDC-2214) o A bispecific antibody project was out-licensed at lead stage to Boehringer IngelhelmExcels working in a multicultural and multidisciplinary matrix organization. Interested in AI augmented drug discovery, Model Informed Drug Development (MIDD) and PK-PD modeling to support critical decision making.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.